Welcome to the Poseidon calculator website!
We have constructed an online calculator that estimates the effect of adding docetaxel to a first-line with platinum and fluoropyrimidine, in patients with histologically confirmed unresectable or metastatic adenocarcinoma of the distal esophagus, gastroesophageal junction (GEJ), or stomach. This tool helps to investigate the profile of patients who can benefit most from docetaxel-based regimens, and contribute to checking the external validity of various clinical trials.
This calculator is intended only for patients with these characteristics; hence, the eligibility criteria will be checked before you can access the calculator.
The data come from a Spanish AGAMENON registry of advanced distal esophagus, GEJ or stomach cancer that represents daily clinical practice patterns among participating institutions. Although this model offers an overview, bear in mind that a minority of your patients may have unusual prognostic factors, which could significantly affect the clinical evolution of the disease. In particular, the administration of the regimen at standard doses up to progression is a basic assumption of the model.
Predictions are merely approximate, so decisions should be made at the discretion of the attending physician.